Seu Guia Visual Meningioma

Entenda este diagnóstico através de dados, infográficos e evidências baseadas na classificação moderna e nas pesquisas atuais.

~1,500
Novos Casos por Ano (EUA est.)
Entendendo Meningioma
What Is CNS Lymphoma & How Is It Classified?
Primary CNS lymphoma (PCNSL) is a rare, aggressive non-Hodgkin lymphoma confined to the CNS. Most cases are diffuse large B-cell lymphoma (DLBCL) with characteristic MYD88 L265P and CD79B mutations. Treatment centers on high-dose methotrexate-based regimens.
CNS Lymphoma
Primary or Secondary?
Primary CNS (PCNSL)
Primary CNS (PCNSL) (~95%)
Confined to CNS, mostly DLBCL
MYD88 L265P CD79B mutated ABC/non-GCB
Secondary CNS
Secondary CNS (~5%)
Systemic lymphoma with CNS spread
Relapsed DLBCL Burkitt Mantle cell
Ocular / Vitreoretinal
Ocular / Vitreoretinal (Subset)
Often precedes or accompanies PCNSL
Vitreoretinal Uveal
Graus Tumorais
CNS Lymphoma Classification
CNS lymphoma is classified as primary (confined to CNS) or secondary (systemic with CNS involvement), with cell of origin and molecular profiling guiding treatment.
1
Primary CNS DLBCL
Most common type (~95% of PCNSL). Diffuse large B-cell lymphoma confined to the brain, eyes, leptomeninges, or spinal cord. ABC/non-GCB phenotype predominates.
2
Vitreoretinal Lymphoma
Intraocular lymphoma often associated with or preceding PCNSL. Presents with vitreous floaters, blurred vision. Requires slit-lamp exam and vitreous biopsy.
3
Leptomeningeal Lymphoma
Lymphoma involving the meninges and CSF. Can be primary or secondary. Presents with cranial neuropathies, headache, hydrocephalus.
4
Secondary CNS Lymphoma
Systemic lymphoma (DLBCL, Burkitt, mantle cell, T-cell) relapsing in or spreading to the CNS. Higher risk with certain subtypes.
5
Intravascular Lymphoma
Rare subtype with lymphoma cells within blood vessel lumens. Can cause stroke-like symptoms, cognitive decline.
6
T-cell CNS Lymphoma
Very rare. Peripheral T-cell lymphomas involving the CNS. Worse prognosis than B-cell PCNSL.
Marcadores Moleculares
Os Principais Biomarcadores
A classificação moderna depende de marcadores moleculares específicos. Cada um revela algo diferente sobre o tumor.
Diagnostic
MYD88
MYD88 L265P
Present in ~70-80% of PCNSL. Activates NF-kB pathway. Targetable with BTK inhibitors. Key diagnostic marker distinguishing PCNSL from other CNS tumors.
~70-80% of PCNSL
Predictive
CD79B
CD79B Mutation
Mutated in ~30-40% of PCNSL. Co-occurs with MYD88. Activates BCR signaling. Predicts response to BTK inhibitors (ibrutinib, zanubrutinib).
~30-40% of PCNSL
Prognostic
BCL6
BCL-6 Rearrangement
Rearrangement or overexpression in a subset of PCNSL. Germinal center marker. May be associated with different biology than MYD88-mutant cases.
Variable
Prognostic
MYC
MYC Rearrangement
MYC rearrangement or amplification associated with aggressive behavior. Double-hit lymphoma (MYC + BCL2/BCL6) confers worse prognosis.
Poor prognostic
Diagnostic
IRF4
IRF4/MUM1
Strongly expressed in PCNSL (>90%). Confirms ABC/non-GCB phenotype. Part of the Hans algorithm for cell-of-origin classification.
>90% of PCNSL
Predictive
PD-L1
PD-L1/CD274
9p24.1 copy number gains and PD-L1 overexpression common in PCNSL. Rationale for checkpoint inhibitor therapy.
~50% of PCNSL
Prognostic
CDKN2A
CDKN2A Deletion
Homozygous deletion associated with worse prognosis in PCNSL. Loss of p16 tumor suppressor function.
Poor prognostic
Prognostic
TP53
TP53 Mutation
Mutations in ~20% of PCNSL. Associated with genomic instability and potentially worse outcomes.
~20% of PCNSL
Sinais & Sintomas
Signs & Symptoms of CNS Lymphoma
PCNSL often presents with rapidly progressive cognitive decline and focal neurological deficits. Symptoms depend on tumor location and extent.

Cognitive / Behavioral

Memory loss, personality changes, confusion, executive dysfunction. Most common presentation due to deep white matter and periventricular location.

Focal Neurological

Hemiparesis, aphasia, visual field deficits depending on tumor location. Often multifocal or deep-seated lesions.

Increased Intracranial Pressure

Headache, nausea, vomiting, papilledema from mass effect or hydrocephalus.

Ocular Symptoms

Blurred vision, floaters, decreased visual acuity. ~15-25% of PCNSL involves the eyes (vitreoretinal lymphoma).

Seizures

Less common than in other brain tumors but can occur, especially with cortical involvement.

CSF / Leptomeningeal

Cranial nerve palsies, radiculopathy from leptomeningeal involvement. CSF cytology may show lymphoma cells.

Diagnóstico
A Jornada Diagnóstica
From first MRI to molecular profiling — the diagnostic pathway for CNS lymphoma.
1

Brain MRI

Contrast-enhanced MRI reveals homogeneously enhancing deep periventricular lesion(s). Often multifocal. DWI shows restricted diffusion.

2

Stereotactic Biopsy

Tissue diagnosis via stereotactic biopsy (NOT resection). Corticosteroids should be avoided before biopsy as they cause tumor lysis.

3

Ophthalmologic Exam

Slit-lamp examination and vitreous biopsy to evaluate for vitreoretinal lymphoma involvement (~15-25% of cases).

4

CSF Analysis

Lumbar puncture for cytology, flow cytometry, protein, and MYD88 mutation testing. Positive in ~15-30%.

5

Staging Workup

CT chest/abdomen/pelvis, bone marrow biopsy, and testicular ultrasound (men >60) to exclude systemic lymphoma.

6

Molecular Profiling

MYD88 L265P and CD79B mutation testing, cell-of-origin (Hans algorithm), MYC/BCL2/BCL6 FISH.

Tratamento
Treatment Options for CNS Lymphoma
Treatment combines high-dose methotrexate-based induction with consolidation. Novel agents are transforming the relapsed/refractory setting.

High-Dose Methotrexate

Backbone of PCNSL treatment. HD-MTX (3.5-8 g/m²) crosses the blood-brain barrier. Often combined with rituximab, cytarabine, and/or thiotepa (MATRix, R-MPV regimens).

Rituximab

Anti-CD20 monoclonal antibody added to HD-MTX backbone. R-MPV (rituximab, MTX, procarbazine, vincristine) and MATRix are standard induction regimens.

Consolidation Transplant

High-dose chemotherapy with thiotepa-based conditioning followed by autologous stem cell transplant (ASCT). Increasingly preferred over WBRT for consolidation.

BTK Inhibitors

Ibrutinib, zanubrutinib, and pirtobrutinib show high response rates in relapsed PCNSL, especially with MYD88/CD79B mutations. Oral agents with CNS penetration.

Whole Brain Radiation

Historically used for consolidation but associated with neurocognitive toxicity. Now typically reserved for elderly or transplant-ineligible patients at reduced doses.

Clinical Trials

Novel agents: CAR-T therapy, bispecific antibodies, lenalidomide, checkpoint inhibitors, and novel combinations for relapsed/refractory disease.

Find matching trials →
Equipe Médica
Sua Equipe Multidisciplinar
CNS lymphoma treatment requires close collaboration between neuro-oncology, hematology/lymphoma, radiation oncology, and ophthalmology.
Especialistas Principais

Neurocirurgião

Realiza cirurgia cerebral para remoção do tumor ou biópsia

Radio-oncologista

Planeja e administra radioterapia de precisão

Neuro-oncologista

Especialista em tumores cerebrais que lidera o planejamento do tratamento

Equipe de Apoio

Neurorradiologista

Interpreta exames de imagem cerebral e orienta o diagnóstico por imagem

Neuropatologista

Analisa o tecido tumoral para determinar o tipo e grau exatos

Enfermeiro(a) Navegador(a)

Orienta sobre consultas, convênios e logística

Recursos
Organizações de Apoio
Organizations providing information, community, and support for CNS lymphoma patients and families.

Lymphoma Research Foundation

Education, support, and research funding for all lymphoma types including PCNSL.

Visit Lymphoma Research Foundation →

National Brain Tumor Society

Leading nonprofit investing in brain tumor research, advocacy, and patient support.

Visit National Brain Tumor Society →

Leukemia & Lymphoma Society

Patient support, financial assistance, and clinical trial navigation for blood cancer patients.

Visit Leukemia & Lymphoma Society →

NCCN Guidelines (CNS Cancers)

Evidence-based clinical practice guidelines for CNS lymphoma management.

Visit NCCN Guidelines (CNS Cancers) →

Quer Explorar Estudos Clínicos?

Pesquise centenas de estudos clínicos e encontre os mais relevantes para seu diagnóstico.

Encontrar Estudos Clínicos →